Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 12 to 15 months of age (not reached their 16th month birthday);~* In good health;~* Parent/guardian available by telephone or for home visits;~* Ability of the parent/guardian to understand and comply with the requirements of the protocol;~* Signed informed consent by parent/guardian; and~* Up to date with the primary series of recommended vaccines per standard clinic practice and local vaccine availability.~Exclusion Criteria:~* Previous known measles, mumps, rubella or varicella disease;~* Previous vaccination against measles, mumps, rubella or varicella disease;~* Hypersensitivity to egg or egg protein;~* Signs or symptoms of any immunosuppressive or immune deficiency disease or ongoing immunosuppressive therapy; or an immunosuppressed individual living in the same household;~* Acute febrile (\>100.0oF \[37.8°C\] oral) illness or clinically significant upper respiratory illness within the 72 hours prior to enrollment;~* Use of aspirin (acetylsalicylic acid) or aspirin-containing products in the month prior to enrollment, or expected use of aspirin while enrolled in this study;~* Administration of any intranasal medication within two weeks prior to enrollment or expected receipt during this study;~* Administration of any live virus vaccine within one month prior to enrollment through 30 days after Visit 3;~* Administration of any inactivated vaccine within two weeks prior to enrollment through 30 days after Visit 3;~* Participation in another investigational trial within one month prior to enrollment or expected enrollment in another investigational trial during this study;~* Receipt of any blood product within three months prior to vaccination or expected receipt within the study duration; and~* Any condition which, in the opinion of the investigator, would interfere with the interpretation or evaluation of the vaccines.~* History of two or more episodes of medically attended wheezing illness by parent/guardian report.~* History of medically attended wheezing illness or bronchodilator medication use within four weeks of enrollment by parent/guardian report.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 15 Months
- Healthy Volunteers: t

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): FluMist
- 3 (Type: PLACEBO_COMPARATOR): Placebo
- 1 (Type: ACTIVE_COMPARATOR): FluMist with other solution

Based on this trial design, predict the completion outcome and termination type (if applicable).